5Y Capital

5Y Capital is a private equity and venture capital firm based in Shanghai, China, specializing in seed, startup, early venture, and growth capital investments. Established in 1992, the firm focuses on a diverse range of sectors, including healthcare, technology, fintech, internet services, consumer services, media, and life sciences, among others. It aims to support entrepreneurs in building innovative companies, particularly in China and other emerging markets in Asia/Pacific. Managing approximately USD 5 billion in dual-currency funds, 5Y Capital attracts investments from global sources, including sovereign wealth funds and family offices. The firm typically makes initial investments exceeding USD 500,000 per portfolio company. 5Y Capital operates under the Morningside Group, which is committed to socially responsible investing, particularly in educational opportunities and scientific research.

W. Anthony Brooke

Director

Zhe Chen

Managing Director

Peter Chen

Managing Director

Yu Cheng

Partner

Ziyou Fu

Investor Relations Professional

Hanson Hu

Investment Manager

Lu Huang

Director

Ted Xutian Jing

Managing Director

Levi Liu Kai

Partner

Yantao Lai

Investment Manager

Wentian Lian

VP

Tony Lian

Investment Manager

Sylvia Liu

Investment Manager

Qin Liu

Co-Founder, Investment Director & Board Member

Richard Liu

Founding Partner

Richard Liu

Founding Partner

Weimin Luo

Partner and Senior Consultant

Ken Shi

Founding Partner

Jianming Shi

Director of Business Development

Kejia Tang

Human Resource Director

Ji Tong

Investment Manager

Sixue Wang

Public Relations and Investor Relations Professional

Qiong Xue

CFO

Joanna Xue

Chief Financial Officer

Dan You

Executive Director

Cloris You Youdan

Managing Director

Elwin Yuan

Partner

Ye Yuan

Partner

Oliver Zhang

Investment Manager

Fisher Zhang

Partner

Fei Zhang

Partner

Bo Zhang

Managing Director

Past deals in Taiwan

Senhwa Biosciences

Series B in 2013
Senhwa Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Founded in 2012 and headquartered in New Taipei City, Taiwan, the company is advancing several drug candidates through clinical trials. Notably, CX-4945 is undergoing phase I/II trials for cholangiocarcinoma in combination with gemcitabine and cisplatin, while CX-5461 is being tested in phase I studies for advanced hematologic malignancies and solid tumors, including breast cancer. Additionally, CX-4945 is involved in trials for advanced basal cell carcinoma and recurrent SHH medulloblastoma through pediatric brain tumor consortium studies. Senhwa Biosciences aims to identify and develop therapies that have the potential to significantly enhance treatment outcomes for patients, focusing on underexploited targets that could improve the standard of care.

Gorilla Technology Group

Series B in 2009
Gorilla Technology Group, Inc. offers a platform that combines video analytics and IoT technology to deliver business intelligence insights for improving performance in sales, operations and understanding of customer needs. Its current clients include Shanghai Media Group. Gorilla Technology Group, Inc. was founded in 2001 and is based in Taipei, Taiwan.

Gorilla Technology Group

Series A in 2007
Gorilla Technology Group, Inc. offers a platform that combines video analytics and IoT technology to deliver business intelligence insights for improving performance in sales, operations and understanding of customer needs. Its current clients include Shanghai Media Group. Gorilla Technology Group, Inc. was founded in 2001 and is based in Taipei, Taiwan.